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P A P E R
SimultaneousMolecular
and Hypoxia Imaging of
Brain Tumors In Vivo
Using Spectroscopic
Photoacoustic Tomography
This noninvasive imaging technology, with high resolution and strong
contrast, promises to open better understanding of the development of
brain tumors and their treatment.
ByMeng-Lin Li, Member IEEE, Jung-Taek Oh, Xueyi Xie, Geng Ku, Wei Wang,
Chun Li, Gina Lungu, George Stoica, and Lihong V. Wang, Fellow IEEE
ABSTRACT | Noninvasive molecular and functional imaging
in vivo is promising for detecting and monitoring various
physiological conditions in animals and ultimately humans. To
this end, we present a novel noninvasive technology, spec-
troscopic photoacoustic tomography (SPAT), which offers both
strong optical absorption contrast and high ultrasonic spatial
resolution. Optical contrast allows spectroscopic separation of
signal contributions from multiple optical absorbers (e.g.,
oxyhemoglobin, deoxyhemoglobin, and a molecular contrast
agent), thus enabling simultaneous molecular and functional
imaging. SPAT successfully imaged with high resolution the
distribution of a molecular contrast agent targeting integrin
v3 overexpressed in human U87 glioblastomas in nude
mouse brains. Simultaneously, SPAT also imaged the hemo-
globin oxygen saturation and the total hemoglobin concentra-
tion of the vasculature, which revealed hypoxia in tumor
neovasculature. Therefore, SPAT can potentially lead to better
understanding of the interrelationships between hemodynam-
ics and specific biomarkers associated with tumor progression.
KEYWORDS | Functional imaging; hemoglobin oxygen satura-
tion; molecular imaging; spectroscopic photoacoustic tomog-
raphy; total hemoglobin concentration
I . INTRODUCTION
Molecular imaging offers an extraordinary opportunity for
studying diseases at the molecular level noninvasively and
quantitatively [1]–[4]. With the marriage of state-of-the-art
noninvasive imaging technologies with molecular- and
cell-biology techniques, the advances emerging from mo-
lecular imaging will enhance our understanding of disease
pathophysiology and lead to better methods for studying
biological processes as well as diagnosing and managing
diseases. For example, molecular imaging offers a more
specific approach to the earlier detection and character-
ization of tumor biology and angiogenesis because it
targets imaging probes at specific molecular markers
expressed on the neoendothelial- and tumor-cell surface.
Such techniques will accelerate the development of novel
molecular-targeted anticancer therapeutics [5]–[8].
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Three common noninvasive molecular imaging do-
mains have been developed more or less in parallel:
magnetic resonance imaging (MRI) [9]–[11], nuclear
imaging (positron emission tomography [12], [13] and
single photon emission computed tomography [14]), and
optical imaging (bioluminescence [15] and fluorescence
imaging [16]–[19]); in addition, ultrasound is also being
developed [20]. Excellent reviews of these technologies are
available in the literature [1]–[4].
Optical imaging is highly attractive owing to its
potential for simultaneous functional and molecular
imaging because endogenous molecules and exogenous
molecular contrast agents can be measured at the same
time. By accessing endogenous oxyhemoglobin (HbO2)
and deoxyhemoglobin (HbR) [21], [22], optical imaging
can offer in vivo noninvasive functional imaging of
blood oxygen saturation (SO2) and total hemoglobin
concentration (HbT). Imaging of the oxygenation status
of tumors, especially hypoxia, is receiving more and more
attention in assessing tumor growth, malignant progres-
sion, metastasis, and resistance to various therapiesV
including radiotherapy and chemotherapy as well as
photodynamic therapy [23]–[27]. By accessing exoge-
nous molecular contrast agents, optical imaging can
offer in vivo noninvasive molecular imaging. Pure optical
imaging, however, faces a major obstacleVthe over-
whelming optical scattering in biological tissue. As a
result, its spatial resolution significantly decreases with
increasing imaging depth, and it cannot image beyond the
intact scalp and cranium of a small-animal head with high
resolution.
Here, we present a novel molecular and functional
imaging techniqueVspectroscopic photoacoustic tomog-
raphy (SPAT)Vfor the detection and characterization of
intracranial tumor xenografts in small animals in vivo.
Photoacoustic tomography overcomes the resolution draw-
back of pure optical imaging while retaining the most
compelling features of both optics and ultrasoundV
namely, high optical absorption contrast and submilli-
meter ultrasound resolutionVup to an imaging depth of
centimeters [28]–[32]. By changing the laser wavelength,
SPAT can probe the optical absorption spectrum of an
object. The measured spectrum can then be used to
decode the contributions from three dominating optical
absorbersVHbR, HbO2, and an exogenous contrast
agentVbased on the differences in their molar optical
extinction spectra. In this paper, the exogenous contrast
agent is an indocyanine-green (ICG) derivative named
IRDye800-NHS (Li-Cor, Inc.) conjugated with cyclic
peptide cyclo(Lys-Arg-Gly-Asp-Phe) [c(KRGDf) for short]
that targets integrin v3; hereafter, it is referred to as
IRDye800-c(KRGDf) [18]. IRDye800 provides both ab-
sorption and fluorescence primarily in the near-infrared
(NIR) spectral region; the former effects a contrast in
SPAT and the latter effects a contrast in fluorescence
imaging. Therefore, SPAT not only can image the level of
the contrast-agent uptake in the brain tumor xenograft,
which is related to the hypermetabolism and angiogenesis
of the tumor, but also can simultaneously image the SO2
and the HbT in the tumor; in addition, conventional
fluorescence imaging can corroborate the contrast-agent
uptake with low spatial resolution.
Subsequent sections will show the following.
1) SPAT can image with high spatial resolution the
distribution of the molecular contrast agent that
targets a brain U87 glioblastoma tumorVwhich
expresses integrin v3Vin a nude mouse
through intact scalp and skull.
2) SPAT can image simultaneously functional pa-
rameters SO2 and HbT in the brain tumor
vasculature without any invasive biological mod-
ification such as opening a cranial window [33].
3) The complementary information from the func-
tional and the molecular imaging can potentially
prove to be useful for tumor diagnosis, prognosis,
and cell-centered therapeutics.
II . MATERIALS AND METHODS
A. Tumor Cells and Animals
Human U87 glioblastoma tumor cells were implanted
stereotactically into young adult immunocompromised
nude mice (Harlan, Co.). The cell line was maintained in
Dulbecco’s Modified Eagle Medium (DMEM) culture
medium with 10 000 units/ml penicillin and 10% fetal
bovine serum (Gibco, Inc.). The implantation was per-
formed on nude mice weighing about 20 grams under
full anesthesia using a mixture of 87 mg/kg ketamine
(Ketaset, Forth Dodge Animal Health) and 13 mg/kg
xylazine (AnaSed, Lloyd Laboratories). One million cells
were inoculated intracranially into the caudate nucleus
at a 3 mm depth from the scalp surface with a volume of
7 l [34].
One week post inoculation, 20 nmol of IRDye800-
c(KRGDf) (University of Texas M. D. Anderson Cancer
Center) [18] was systematically administered through the
tail vein with mannitol, which permealized the blood brain
barrier. Imaging was conducted 20 h after the injection
of IRDye800-c(KRGDf). Throughout the SPAT experi-
ment, the mouse was under full anesthesia and provided
with oxygen; the body temperature of the nude mouse was
maintained at 37 using a water heating pad; the pulse rate
and arterial blood oxygenation were monitored using a
pulse oximeter (Model 8600, Nonin Medical, Inc.)
clamped on the back paw. After the experiment, the
mouse was sacrificed; the mouse brain was harvested to
make slides. The slides were divided into three interlaced
groups. One group were imaged using the Odyssey
fluorescence imaging system at 800 nm to verify the
IRDye800-c(KRGDf) uptake. The other two groups were
fixed; then, one group was stained with Thionine to
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identify the tumor and the other group were stained with
anti–von Willebrand factor VIII antibody to demonstrate
the tumor-associated neovascularization.
All of the experimental animal procedures on nude
mice were approved by the University Laboratory Animal
Care Committee of Texas A&M University and were
performed according to the guidelines of the U.S. National
Institutes of Health [35].
B. SPAT System for Noninvasive Imaging of
Mouse Brain In Vivo
The experimental setup of in vivo SPAT of a nude
mouse head is shown in Fig. 1. A tunable Ti:sapphire (Ti:
Sa) nanosecond pulsed laser (LT-2211A, Lotis T II, Minsk,
Belarus) pumped by an Nd:YAG laser (LS-2137/2, Lotis T
II, Minsk) was employed to provide laser pulses with a
pulse repetition frequency (PRF) of 10 Hz. The prism-
directed laser beam was expanded by a concave lens,
homogenized by a light diffuser, and then delivered to the
animal head. The incident energy density of the laser beam
on the surface of the mouse head was controlled at
20 mJ/cm2 according to the ANSI standard [36]. The
energy of each laser pulse was detected by a photodiode
(PD) (DET110, ThorLabs, Inc.) and recorded by an
oscilloscope (TDS5054, Tektronix, Inc.). The recorded
PD signals were used to normalize the received PA signals;
thus, the effect of laser energy fluctuation is compensated
for. The nude mouse was restrained by a homemade mount
and coated with a thin layer of ultrasonic coupling gel;
then, its head protruded into the water tank through a hole
in the bottom, where the hole was sealed with a piece of
polyethylene membrane. Two ultrasonic transducers
(V323/2.25 MHz and XMS-310/10 MHz, Panametrics)
within the water tank detected the PA signals. The active
areas of the 2.25- and 10-MHz transducers were 6 and
2 mm in diameter, respectively; the corresponding
nominal bandwidths were 66% and 80%, respectively. A
computer-controlled step motor rotated the two trans-
ducers through 120 positions along a complete circle to
receive the PA signals at each position. These signals
were low-pass filtered and amplified by ultrasonic receiv-
ers (5072PR, Panametrics). The amplified signals were
then digitized and averaged 20 times at each scan position
with a data acquisition card (CS14100, Gage, Inc.)
operating at a 50-MHz sampling rate with 14-bit resolu-
tion. After a full circle is scanned, the digitized signals
were used to reconstruct the distribution of the optical
absorption in the imaging (x-y) plane with a modified
back-projection algorithm [37].
Both the oscilloscope and the data acquisition card
were synchronized by the Q-switch synchronization
output from the pumping laser. The 2.25-MHz transducer
was positioned at approximately the height of the tumor
inoculation (3 mm below the scalp surface) with a
scanning radius of 4.5 cm to image the tumor. The 10-MHz
transducer was located approximately at the height of the
scalp surface with a scanning radius of 3.5 cm to image the
brain cortex. Four laser wavelengthsV764, 784, 804, and
824 nmVwere used. The wavelength was automatically
changed at each scanning position, instead of at the end of
each circular scan, to reduce motion artifacts. In addition,
the laser beam was blocked by a computer-controlled
shutter during the translation of the transducer to reduce
laser exposure of the tissue and laser bleaching of the
contrast agent.
C. Principle of SPAT Imaging of HbR, HbO2, and
IRDye800-c(KRGDf)
SPAT separates the contributions from multiple
absorbers based on the differences in their molar optical
extinction spectra. Upon the administration of IRDye800-
c(KRGDf), only three dominant absorbers [HbR, HbO2,
and IRDye800-c(KRGDf)] are imaged in the NIR spectral
region. After being normalized by both the incident laser
energy and the attenuation of the laser energy due to the
skin and skull, the reconstructed PA image Aði; x; yÞ at the
ith wavelength i can be expressed as
Aði; x; yÞ ¼ "HbRðiÞCHbRðx; yÞ þ "HbO2ðiÞCHbO2ðx; yÞ
þ "IRDyeðiÞCIRDyeðx; yÞ (1)
apart from a constant factor. Here, "HbRðiÞ, "HbO2ðiÞ,
and "IRDyeðiÞ are the known molar extinction coefficients
(cm1M1) of HbR, HbO2, and IRDye800-c(KRGDf) at
wavelength i, respectively (for the molar extinction
spectra of the three absorbers, see Fig. 2). CHbRðx; yÞ,
CHbO2ðx; yÞ, and CIRDyeðx; yÞ are the molar concentrations
(M) of HbR, HbO2, and IRDye800-c(KRGDf), respec-
tively. Using multiwavelength measurements, CHbRðx; yÞ,
CHbO2ðx; yÞ, and CIRDyeðx; yÞ can be estimated by solving
the overdetermined set of linear equations, four equationsFig. 1. Experimental setup of SPAT for in vivo mouse brain imaging.
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With the estimated CHbRðx; yÞ and CHbO2ðx; yÞ, the
HbT and SO2 images can be calculated point by point as
follows [38]:
HbTðx; yÞ ¼ CHbO2ðx; yÞ þ CHbRðx; yÞ; (3)
SO2ðx; yÞ ¼ CHbO2ðx; yÞ
CHbO2ðx; yÞ þ CHbRðx; yÞ
: (4)
Note that HbT here represents the total amount of
hemoglobin within the resolution cell. Further compensa-
tion for the cumulative effect of hemoglobin and contrast
agent absorption along the light paths in the above analysis
should provide better accuracy of estimation. In the
following SO2 image, the vasculature is first segmented
from the background based on the reconstructed HbT
distribution; then, its SO2 distribution is computed.
III . RESULTS
A. In Vivo SPAT Molecular Imaging of
Integrin v3 in Brain Tumors
Previous reports suggest that integrin v3, which is
overexpressed in newly formed tumor microvesesels,
plays an important role in tumor progression, angio-
genesis, and metastasis [39]–[41]. Our in vivo molecular
imaging strategy targets a U87 glioblastoma tumor with
IRDye800-c(KRGDf). The binding of IRDye800-
c(KRGDf) to U87 tumor cells was proven in vitro by a
binding assay (Fig. 4).
We noninvasively imaged in vivo the brains of young
adult immunocompromised nude mice (Harlan, Co.)
containing intracranial U87 glioblastoma xenografts one
week after inoculation of tumor cells. As a negative
control, SPAT imaged the mice before the administration
of IRDye800-c(KRGDf) and showed no signal from the
contrast agent as expected. Twenty hours after the
administration of IRDye800-c(KRGDf) through the tail
vein, the mice were imaged first by a conventional planar
fluorescence imaging system and then by the SPAT system.
Then the brain was harvested for validation.
Fig. 3(a) shows a segmented fluorescence image super-
imposed onto a white-light photograph. Before segmenta-
tion, the fluorescence intensity in the tumor focus is about
1.7 times higher than that in the normal brain background.
This image verifies the uptake of the IRDye800-c(KRGDf)
in the U87 glioblastoma tumor. Fig. 3(b) and (c) shows an
in vivo SPAT molecular image of IRDye800-c(KRGDf) and
a composite SPAT image made by superimposing the
segmented molecular image of IRDye800-c(KRGDf) on
the structural image of the brain cortex, respectively. The
structural image was the SPAT image acquired at 804 nm.
It is clearly seen that the contrast agent is mainly accu-
mulated at the tumor focus. Fig. 3(d) shows a photograph
of the excised nude mouse brain with the U87 glio-
blastoma tumor; the tumor focus can be seen on the right
hemisphere of the brain. The tumor positions in Fig. 3(c)
and (d) agree. Fig. 3(e) shows a microfluorescence image
of a frozen brain section acquired postmortem using a
fluorescence imaging system (Odyssey; Li-Cor, Inc.). The
depth of this section is1 mm below the surface of the brain
cortex or 3 mm beneath the scalp surface. This image
verifies again the uptake of the molecular probe. Fig. 3(f)
shows a photograph of a Thionine-stained section of the
excised nude mouse brain, which was sliced from approx-
imately the same depth as the section for Fig. 3(e). This
Fig. 2. Molar extinction coefficient spectra of 10 M
IRDye800-c(KRGDf) in plasma, 20 M IRDye800-c(KRGDf)
in plasma, HbO2, and HbR. Note that the values of HbO2 and
HbR are scaled up by two orders of magnitude for comparison
with IRDye800-c(KRGDf). (For lists of values of HbO2 and HbR,
refer to http://www.omlc.ogi.edu/spectra/.)
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histological evaluation further reveals the depth and location
of the U87 glioblastoma tumor.
For Fig. 3(c), two ultrasonic transducers with different
center frequencies were used to achieve both high spatial
resolution for structural imaging and high sensitivity for
molecular imaging [31], [32]. A 10-MHz transducer
provided the structural image of HbT with a 60-m in-
plane resolution, whereas a lower-frequency 2.25-MHz
transducer provided the molecular image with a 312-m
in-plane resolution. Both resolutions are significantly
better than that in the fluorescence image [Fig. 3(a)].
B. In Vivo SPAT Hypoxia Imaging in
Brain Tumor Vasculature
Fig. 5(a) and (b) shows the SO2 and HbT images,
respectively, of the nude mouse brain shown in Fig. 3.
The tumor focus shows lower SO2 than the surrounding
normal tissue, which indicates hypoxic tumor vasculature;
it also shows higher HbT, which indicates probable
angiogenesis. The hypoxic area in Fig. 5(a) is slightly
larger than the uptake area of IRDye800-c(KRGDf) in
Fig. 5(b), possibly because hypermetabolism affects the
blood supply of not only the tumor proper but also the
periphery.
The SO2 and HbT of normal and tumor vasculatures can
be quantitatively compared. Fig. 5(c) plots the averages and
standard deviations of SO2 in the normal and tumor
vasculatures of the brain from three mice; the average SO2
in the tumor vasculature is at least 13% lower than that in
the normal vasculature; the SO2 level in the tumor vas-
culature is more heterogeneous than that in the normal
vessels, as indicated by the error bars. The absolute HbT
levels cannot be compared among the three mice because
they depend on the different conditions of oxygen in-
halation and anesthesia. Hence, a relative HbT (rHbT)V
defined as the ratio of the local HbT to the mean HbT in the
medium fissure of each mouseVis adopted. Fig. 5(d) plots
SO2 versus rHbT in the normal and tumor vasculatures of
the brain. The normal vessels tend to have a lower rHbT in
addition to a higher SO2 and a lower SO2 fluctuation than
the tumor vessels.
Fig. 4. In vitro binding of IRDye800-c(KRGDf) to U87 tumor cells
expressing integrin v3. (a) Fluorescence microscopic image of
U87 cells incubated with 6 M of IRDye800-c(KRGDf) for 3 min.
(b) Fluorescence microscopic image of U87 cells incubated with an
excess 1.2 mM of c(KRGDf) for 5 min followed by 6 M of
IRDye800-c(KRGDf) for 3 min. Red: IRDye800-c(KRGDf);
green: Sytox green-labeled cell nuclei.
Fig. 5. In vivo functional imaging of a nude mouse brain with a
U87 glioblastoma xenograft by SPAT. (a) SO2 image of the
nude mouse brain shown in Fig. 3. The red arrow indicates the
hypoxic region. (b) HbT image of the same nude mouse brain.
(c) Comparison of normal and tumor vasculatures in SO2 from
triplicate mice. Three normal and three tumor vessels were chosen
from each SO2 image for the calculation. Error bar: one standard
deviation. (d) The SO2 versus the relative HbT in normal and
tumor vasculatures from the same triplicate mice as in (b).
Fig. 3. In vivo molecular imaging of a nude mouse brain with a
U87 glioblastoma xenograft by SPAT and validations. (a) Composite
of segmented conventional fluorescence image and white-light
photograph of the nude mouse head acquired in vivo 20 h after
intravenous injection of IRDye800-c(KRGDf). (b) In vivo SPAT
molecular image of IRDye800-c(KRGDf). (c) Composite of segmented
molecular image of IRDye800-c(KRGDf) and structural image, both
acquired in vivowith SPAT. (d) Photograph of the excised nudemouse
brain acquired postmortem. (e) Microfluorescence image of a frozen
brain section 1 mm below the brain cortex. (f) Photograph of a
Thionine-stained brain section 1 mm below the brain cortex. The
dashed circles indicate the locations of the glioblastoma xenograft.
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IV. DISCUSSION
The experimental results validated that SPAT can image
integrin v3 conjugated with optical contrast agent in the
nude mouse brain with high spatial resolution on a
significant depth scale relative to pure optical imaging
(e.g., fluorescence imaging). The imaged inhomogeneous
distribution of the v3-targeted contrast agent at the
tumor focus implies vascular heterogeneities in solid brain
tumors. This SPAT-based molecular imaging has the
potential to unravel noninvasively neoangiogenesis inside
the brain to detect early stage cancer and to assess invasive
potential at the molecular level since integrin v3, in
addition to other factors, is incriminated in facilitating
angiogenesis, tumor progression, and metastasis.
Photoacoustic imaging was reported to possess molar
sensitivities of ICG in phantoms on the order of nano M
[42] to M [32]. An in vivo sensitivity of 2 fmol of ICG
in a resolution cell in the blood stream was also reported
[43]. We demonstrated the imaging of 5-M IRDye800-
c(KRGDf) in 250-m inner diameter plastic tubes
covered by a slab of chicken tissue of 2 mm in
thickness with a signal-to-noise ratio of 26 dB (see
Fig. 6). As a result, the sensitivity of our SPAT system to
IRDye800-c(KRGDf) is 5 fmol in a resolution cell. Of
course, the sensitivity depends on the SPAT parameters;
for example, increasing the incident laser energy density
toward the maximum permissible exposure can improve
the sensitivity [36]. Fig. 6 also verified the efficacy of
SPAT in separating the signal contributions from
IRDye800-c(KRGDf) and blood; the efficacy can poten-
tially be improved further by the use of more optical
wavelengths at the expense of data acquisition time.
Tumor hypoxia revealed by the functional imaging aspect
of SPAT can be correlated with the invasion of the U87
glioblastoma cells revealed by the molecular imaging aspect
of SPAT. In a separate rat model demonstrating the
etiopathogenesis of hypoxia in intracranial tumor xeno-
grafts, we evaluated the expressions of the hypoxia-inducible
factor-1 (HIF-1), the vascular endothelial growth factor
(VEGF), the vascular endothelial growth factor receptor
2 (VEGFR2), and the matrix metalloproteinases-9
(MMP-9) proteins and the associated mRNA levels [26]
in hypoxic brain tumor foci [44]; the levels of these
proteins and the associated mRNA in the brain tumor foci
were found to be higher than those in normal brain tissues.
This model supports the SPAT data that show both hypoxia
and up-regulation of proteins in the brain tumor foci.
Higher HbT in addition to lower SO2 in the tumor
vasculature is observed, as reported in other studies [45], by
SPAT. A tumor requires more blood to meet its up-regulated
metabolism, which results in higher HbT. Thus, simulta-
neous imaging of both HbT and SO2 as well as biomarkers
such as integrin v3 provide complementary information
about tumor biological properties, which can be potentially
useful for cell-centered diagnosis, prognosis, and therapies.
The major limitation of our current SPAT system is
the scanning speed. Owing to the low laser PRF, slow
wavelength changing, and time-consuming mechanical
scanning, the current scanning time is about one hour if
four wavelengths, 20 times signal averaging, and 120 scan-
ning steps are used. Faster imaging, however, can be
achieved by improving these speed-related factors.
V. CONCLUSIONS
In summary, we have shown that SPAT provides a new
paradigm to high-resolution simultaneous molecular and
functional imaging of intracranial brain tumors in small
animals in vivo. In the present SPAT system, the spatial
resolution is 312 m for molecular and functional
imaging and 60 m for structural imaging. SPAT may
be of great importance in the future for monitoring the
development of hypoxia in brain tumors and determining
the most suitable type and timing of therapy. Further
system improvements can potentially shed new light on
in vivo hemodynamics and biochemical reactions. This
paper should prove to be a new impetus for the molecular
imaging community to tailor molecular imaging strategies
based on optical absorption. SPAT holds promise for non-
invasivemonitoring of pathological or physiological reactions
(e.g., apoptosis) at the cellular and molecular level. In addi-
tion, SPAT is applicable to imaging of gene expression [46] or
to monitoring of delivery of vectors to specific cells in gene
therapy. We anticipate that SPAT will make profound
contributions to the molecular imaging in general.
A. Supplementary Information
Method: For the in vitro binding assay of IRDye800-
c(KRGDf) to U87 cells expressing integrin v3, U87 cells
were seeded on cover slips in 24-well plates and incubated
Fig. 6. Imaging of gelatin-embedded 250-m inner diameter tubes
containing IRDye800-c(KRGDf), oxygenated blood, or a mixture
of the two, where the tubes were covered by a slab of chicken tissue
of 2 mm in thickness. (a) Structural image acquired by SPAT at
the 804-nm optical wavelength. All tubes were visualized.
1) oxygenated blood, 2) 10 M IRDye800-c(KRGDf), 3) 5 M
IRDye800-c(KRGDf), 4) one-to-one mixture of blood and 10 M
IRDye800-c(KRGDf). (b) Distribution of IRDye800-c(KRGDf) estimated
by SPAT with four wavelengthsV764, 784, 804, and 824 nm.
In the image, IRDye800-c(KRGDf) was clearly visible while blood was
significantly rejected. (c) Fluorescence image of IRDye800-c(KRGDf).
The tubes are invisible because conventional fluorescence imaging
cannot achieve high spatial resolution in strong scattering tissue.
Li et al. : Simultaneous Molecular and Hypoxia Imaging of Brain Tumors In Vivo
486 Proceedings of the IEEE | Vol. 96, No. 3, March 2008
in DMEM/F-12 culture medium (0.5 mL/well) overnight.
IRDye800-c(KRGDf) at a concentration of 6 M was
added to each well for 3 min. The cells were washed twice
with phosphate-buffered saline (PBS) and incubated in a
solution of Sytox green in 95% ethyl alcohol (1 M,
Molecular Probes) for 15 min to fix and stain the cell
nuclei. The cells were washed again with PBS; then, the
cover slips were mounted for microscopic examination.
For the blocking test, 1.2 mM of unconjugated c(KRGDf)
was added to the culture medium 5 min before the
addition of IRDye800-c(KRGDf).
Results: As shown in the binding test (a), IRDye800-
c(KRGDf) bound to U87 cells. As shown in the blocking
test (b), no IRDye800-c(KRGDf) was uptaken because the
unlabelled c(KRGDf) preemptively blocked the v3
receptors of the U87 cells. h
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